News
Media
Peer ExchangeCase-Based Psych PerspectivesClinical Case CollectiveInsightsPeers & PerspectivesSlideshowsVideos
Conferences
Conference CoverageConference Listing
Publication
Psychiatric Times
More
Job Board
CME/CE
Partners
Editorial
Resources
Between the LinesExpert PerspectivesClinical ConsultClinical ScalesInteractive ToolsLive EventsPartner PerspectivesQ&AQuizzesSeriesSpecial ReportsSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Publication
  • Job Board
  • CME/CE
  • Partners
  • Editorial
  • Resources
  • Subscribe
  • ADHD
  • Addiction & Substance Use
    • Gambling
    • Opioid Related Disorders
    • Alcohol Abuse
    • Amphetamine Related Disorders
    • Substance Use Disorder
  • Alzheimer Disease
  • Anxiety & Stress Disorders
    • Disaster Psychiatry
    • Panic Disorder
    • Trauma And Violence
    • Traumatic Stress Disorders
  • Bipolar Disorder
    • Mania
  • COVID-19
  • Cannabis
  • Case Discussions
  • Child & Adolescent Psychiatry
  • Climate Change
  • Comorbidity
  • Compulsive Disorders
  • Cultural Psychiatry
  • Digital Therapeutics
  • Diversity, Equity, Inclusion
  • Drug Watch
  • Eating Disorders
  • Emergency Psychiatry
  • Ethics
  • Forensic Psychiatry
    • Munchausen Syndrome
    • Sexual Offenses
  • Geriatric Psychiatry
  • Integrative Psychiatry
  • Major Depressive Disorder
  • Media & Psychiatry
  • Mental Health Awareness Month
  • Mood Disorders
  • Neuropsychiatry
    • Cognitive Disorders
    • Dementia
    • Autism
  • PTSD
  • Personality Disorders
    • Compulsive Personality Disorder
    • Dependent Personality Disorder
    • Dissociative Identity Disorder
    • Histrionic Personality Disorder
    • Schizoid Personality Disorder
    • Antisocial Personality Disorder
    • Borderline Personality
  • Postpartum Depression
  • Psychedelics
  • Psychopharmacology
  • Psychosomatics
    • Delirium
    • Metabolic Disorders
    • Somatoform Disorder
  • Psychotherapy
    • Cognitive Behavioral Therapy
  • Schizophrenia/Psychosis
    • Paranoid Schizophrenia
    • Psychotic Affective Disorders
    • Schizoaffective
    • Schizophrenia Psychotic Features
    • Schizotypal Personality Disorder
    • Catatonic Schizophrenia
  • Sleep Disorders
    • Narcolepsy
    • Nocturnal Paroxysmal Dystonia
    • Sleep Deprivation
    • Sleep Wake Transition
    • Circadian Rhythm Sleep Disorders
  • Special Populations
    • Pervasive Developmental Disorder
    • LGBTQ+
    • Gender Issues
    • Military Mental Health
  • Sports Psychiatry
  • Suicide
  • Tardive Dyskinesia
  • Technology & Psychiatry
    • Artificial Intelligence
  • Transcranial Magnetic Stimulation
Spotlight -
Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|
Major Depressive Disorder
Advertisement
|Articles|February 4, 2011

Are You EHR-Ready? Quiz

Is your practice ready to begin the EHR transition? Take this simple quiz to find out.

Advertisement

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!
Advertisement

Related Content

Advertisement
clinical trial

Analyzing a Randomized Controlled Trial

ByRandall F. Moore, MD, JD,John S. White, MD
December 15th 2025
mental disorder

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa
December 3rd 2025
catatonia

Poll: Has the Shortage of IV Ativan Impacted Your Practice?

ByPsychiatric Times Editors
November 5th 2025
November Theme: Best Practices

Presenting Our November Theme: Best Practices

ByLeah Kuntz
November 3rd 2025
path forward

Preparing for the Future: The Psychiatric Workforce

ByMichael Asbach, DMSc, PA-C, Psych-CAQ,Mitchell Anderson, PA-S,Citlalli Marin, PA-S
June 11th 2025
Advertisement
Advertisement

Trending on Psychiatric Times

1

Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia

2

Cobenfy for Treatment of Schizophrenia Now Approved in China

3

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

4

Latest Alzheimer Disease Data: Reports from CTAD 2025

5

FDA Recommends Additional Phase 3 Trial for Brilaroxazine for Schizophrenia

  • About
  • Advertise
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us